How did AtaiBeckley's stock react to the acquisition news?

The stock surged 33.4% on the announcement day and is up 84.75% year-to-date.

Why is Eli Lilly acquiring AtaiBeckley?

Eli Lilly aims to strengthen its neuroscience pipeline and leverage AtaiBeckley's AI-driven drug development platform.

Eli Lilly to Acquire AtaiBeckley in Deal Worth Up to $3.8 Billion

Eli Lilly (LLY) has reached an agreement to acquire AtaiBeckley (ATAI) in a cash and contingent value rights deal valued at up to $3.8 billion. ATAI shares jumped 33.4% on the day of the announcement and are up 84.75% year-to-date.

July 17, 2026

2 min read

Source: Simply Wall St.

Key Numbers

deal value

3.8B

one day return

33.4%

ytd return

84.75%

one year return

156.27%

Eli Lilly and Company has agreed to acquire AtaiBeckley (NasdaqGM: ATAI) in a cash and contingent value rights (CVR) deal valued at up to $3.8 billion. The acquisition aims to bolster Eli Lilly's pipeline in neuroscience and mental health treatments.

Deal Details

Item	Details
Total Value	Up to $3.8 billion
Payment Method	Cash + Contingent Value Rights
Premium	Not disclosed
Expected Close	Not yet announced

Rationale

Eli Lilly seeks to enhance its pipeline in neurological and psychiatric treatments, particularly amid growing demand for depression and anxiety therapies. AtaiBeckley brings an AI-driven platform for developing novel psychiatric drugs, which could accelerate innovation at Eli Lilly.

Regulatory Challenges

The deal is expected to face antitrust reviews in the U.S. and Europe. Neither company has disclosed any regulatory hurdles yet, but legal experts suggest the acquisition may face scrutiny due to Eli Lilly's market influence.

Impact on Stocks

ATAI shares surged 33.4% on the announcement day, reflecting investor optimism. The stock is up 84.75% year-to-date and 156.27% over the past year. In contrast, LLY shares showed no significant movement following the news.

Frequently Asked Questions

The deal is valued at up to $3.8 billion, including cash and contingent value rights.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.